scholarly article | Q13442814 |
P50 | author | Kouichi Hosomi | Q92147598 |
Kazutaka Ushio | Q92147600 | ||
P2093 | author name string | Lili Mao | |
Mitsutaka Takada | |||
Mai Fujimoto | |||
Juran Kato | |||
P2860 | cites work | 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. | Q35698498 |
Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events | Q36804419 | ||
Novel statistical tools for monitoring the safety of marketed drugs | Q36835511 | ||
In silico methods for drug repurposing and pharmacology | Q36837816 | ||
Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. | Q37056204 | ||
Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. | Q37511294 | ||
Systems pharmacology of adverse event mitigation by drug combinations | Q37658567 | ||
Cytokines in inflammatory bowel disease | Q39206254 | ||
Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database | Q40075147 | ||
Lipopolysaccharide induces CXCL2/macrophage inflammatory protein-2 gene expression in enterocytes via NF-kappaB activation: independence from endogenous TNF-alpha and platelet-activating factor | Q40268445 | ||
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease | Q41215282 | ||
The emergence of genome-based drug repositioning | Q42080559 | ||
Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis | Q46072124 | ||
Treatment of ulcerative colitis with thioproperazine. | Q48894542 | ||
Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates | Q24647071 | ||
Connections in pharmacology: innovation serving translational medicine | Q27008514 | ||
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 | ||
Navigating chemical space for biology and medicine | Q28298611 | ||
Systematic drug repositioning based on clinical side-effects | Q28478506 | ||
The Connectivity Map: a new tool for biomedical research | Q28530408 | ||
OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications | Q28551997 | ||
A survey of current trends in computational drug repositioning | Q28602324 | ||
Ontology-Based Meta-Analysis of Global Collections of High-Throughput Public Data | Q28749098 | ||
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 | ||
Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
Computational and experimental advances in drug repositioning for accelerated therapeutic stratification | Q30487562 | ||
Computational drug repositioning: from data to therapeutics | Q30594820 | ||
Data mining of the public version of the FDA Adverse Event Reporting System | Q30651235 | ||
Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database | Q30803396 | ||
Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases | Q31040399 | ||
Prevention of antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism | Q31097538 | ||
Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases | Q31144205 | ||
Discovery and preclinical validation of drug indications using compendia of public gene expression data | Q33995422 | ||
Diagnosing the decline in pharmaceutical R&D efficiency | Q34257771 | ||
The many roles of computation in drug discovery | Q34307063 | ||
Applications of Connectivity Map in drug discovery and development | Q34378751 | ||
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. | Q34629802 | ||
Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database | Q35069176 | ||
Exploiting drug-disease relationships for computational drug repositioning | Q35109885 | ||
NF-κB in the regulation of epithelial homeostasis and inflammation | Q35347805 | ||
A Bayesian neural network method for adverse drug reaction signal generation. | Q52238255 | ||
Changing Trends in Computational Drug Repositioning. | Q55717464 | ||
The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection | Q57305014 | ||
Can you teach old drugs new tricks? | Q59080940 | ||
The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization | Q61964816 | ||
Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis | Q71666481 | ||
Animal models of inflammatory bowel disease | Q82786536 | ||
Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates dextran sulfate sodium-induced colitis in mice | Q82881419 | ||
A review of connectivity map and computational approaches in pharmacogenomics | Q87648094 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e0204648 | |
P577 | publication date | 2018-10-09 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs | |
P478 | volume | 13 |